Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: A meta-analysis of randomized clinical trials

Keeley, 2003, Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials, Lancet, 361, 13, 10.1016/S0140-6736(03)12113-7 Gruentzig, 1979, Nonoperative dilation of coronary artery stenosis: percutaneous transluminal coronary angioplasty, N Engl J Med, 301, 61, 10.1056/NEJM197907123010201 1998, Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes: platelet glycoprotein IIb/IIIa in unstable angina: Receptor Suppression Using Integrilin Therapy, N Engl J Med, 339, 436, 10.1056/NEJM199808133390704 Anderson, 2007, ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 50, e1, 10.1016/j.jacc.2007.02.013 Rao, 2004, Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes, JAMA, 292, 1555, 10.1001/jama.292.13.1555 Eikelboom, 2006, Adverse impact of bleeding on prognosis in patients with acute coronary syndromes, Circulation, 114, 774, 10.1161/CIRCULATIONAHA.106.612812 Manoukian, 2007, Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial, J Am Coll Cardiol, 49, 1362, 10.1016/j.jacc.2007.02.027 Fox, 1993, Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans, Thromb Haemost, 69, 157, 10.1055/s-0038-1651573 Stone, 2008, Bivalirudin during primary PCI in acute myocardial infarction, N Engl J Med, 358, 2218, 10.1056/NEJMoa0708191 Lincoff, 2003, Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial, JAMA, 289, 853, 10.1001/jama.289.7.853 Stone, 2006, Bivalirudin for patients with acute coronary syndromes, N Engl J Med, 355, 2203, 10.1056/NEJMoa062437 Gibson, 2006, A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial, J Am Coll Cardiol, 47, 2364, 10.1016/j.jacc.2005.12.077 Lincoff, 2002, Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET), Am Heart J, 143, 847, 10.1067/mhj.2002.122173 Chew, 2003, Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials, Am J Cardiol, 92, 919, 10.1016/S0002-9149(03)00970-6 Ebrahimi, 2005, Bivalirudin vs heparin in percutaneous coronary intervention: a pooled analysis, J Cardiovasc Pharmacol Ther, 10, 209, 10.1177/107424840501000401 Antman, 2003, Should bivalirudin replace heparin during percutaneous coronary interventions (letter)?, JAMA., 289, 903, 10.1001/jama.289.7.903 Bittl, 2006, Accounting for ACUITY (letter), N Engl J Med, 355, 2249, 10.1056/NEJMe068227 Topol, 1997, Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention, JAMA, 278, 479, 10.1001/jama.1997.03550060055036 Lincoff, 1999, Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one year outcome in the EPILOG trial, Circulation, 99, 1951, 10.1161/01.CIR.99.15.1951 Mehran, 2009, Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomized controlled trial, Lancet, 374, 1149, 10.1016/S0140-6736(09)61484-7 Stone, 2007, Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management, JAMA, 298, 2497, 10.1001/jama.298.21.2497 Robson, 2002, Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender, Clin Pharmacol Ther, 71, 433, 10.1067/mcp.2002.124522 Chew, 2001, Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials, Circulation, 103, 961, 10.1161/01.CIR.103.7.961 Coats, 2009, Ethical authorship and publishing, Int J Cardiol, 131, 149, 10.1016/j.ijcard.2008.11.048